Clinical trial
A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients
NCT04416516 is registered in ClinicalTrials.gov with Ascend Biopharmaceuticals Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2A Study to Assess the Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor in the Treatment of Multiple Low Risk Basal Cell Carcinomas in Sporadic or Basal Cell Nevus Syndrome Patients
- Lead sponsor
- Ascend Biopharmaceuticals Ltd
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 16, 2020
- Completion date
- February 14, 2024
- Enrollment
- 21 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.